ArticleScientific reports2025
Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Paclitaxel Drug-Coated Balloon Angioplasty for Medically Refractory Intracranial Atherosclerotic Disease: A US Single-Center Experience With the AGENT Balloon.Stroke (Hoboken, N.J.) · 2026Article
- Pre-procedural C-reactive protein levels and carotid or intracranial artery restenosis: A systematic review and meta-analysis.Atherosclerosis plus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paclitaxel-coated balloon (PCB) treatment has shown promise for intracranial atherosclerotic disease (ICAD). However, studies on restenosis and its associated factors after PCB use are lacking. This study aimed to elucidate risk factors of restenosis after PCB treatment for ICAD. We retrospectively enrolled consecutive patients who had been successfully treated with PCBs for symptomatic ICAD between January 2016 and December 2022. Eligible patients were classified into "no-restenosis" and "restenosis" groups by follow-up DSA. Demographic, clinical, laboratory test, and angiographic data were analyzed. Multivariate logistic regression analysis was used to explore the risk factors of restenosis after PCB treatment. A total of 261 eligible patients were enrolled in this study. There was no death and there were 6.51% (17/261) patients had ipsilateral stroke within 30 days. During 6 months clinical follow up, there was no death and there were 3.07% (8/261) patients had ipsilateral stroke after 30 days, and 13.41% (35/261) patients were identified with restenosis. The restenosis group had significantly higher follow-up hs-CRP (P = 0.040), higher stenosis degree (P = 0.011), higher total occlusion rate (P = 0.009), longer lesion length (P < 0.001), higher residual stenosis after intervention (P < 0.001) and lower stenting rate (P = 0.017).Multivariate logistic regression analysis showed that baseline neutrophil count (OR 1.356, 95% CI 1.015-1.812; P = 0.039), lesion length (OR 1.113, 95% CI 1.032-1.199; P = 0.005) and residual stenosis after intervention (OR 1.066, 95% CI 1.036-1.097; P < 0.001) were risk factors of restenosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.